Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial

✍ Scribed by André, Fabrice (author);O'Regan, Ruth (author);Ozguroglu, Mustafa (author);Toi, Masakazu (author);Xu, Binghe (author);Jerusalem, Guy (author);Masuda, Norikazu (author);Wilks, Sharon (author);Arena, Francis (author);Isaacs, Claudine (author);Yap, Yoon Sim (author);Papai, Zsuzsanna (author);Lang, Istvan (author);Armstrong, Anne (author);Lerzo, Guillermo (author);White, Michelle (author);Shen, Kunwei (author);Litton, Jennifer (author);Chen, David (author);Zhang, Yufen (author);Ali, Shyanne (author);Taran, Tetiana (author);Gianni, Luca (author)

• Book ID: 121745669
• Publisher: Lancet Publishing Group
• Year: 2014
• Tongue: English
• Weight: 478 KB
• Volume: 15
• Category: Article
• ISSN: 1470-2045
• DOI: 10.1016/S1470-2045(14)70138-X